instruction stringclasses 3
values | input stringlengths 1 1.34k | output stringlengths 76 928 |
|---|---|---|
Identify the potential clinical side effects associated with this chemical compound. | CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O | This compound may cause the following side effects: Metabolism and nutrition disorders, Eye disorders, Investigations, Musculoskeletal and connective tissue disorders, Gastrointestinal disorders, Immune system disorders, Reproductive system and breast disorders, Neoplasms benign, malignant and unspecified (incl cysts a... |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC(Oc1ccc(Cl)cc1Cl)C(=O)O | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | Clc1ccc(C(Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 | This compound is toxic. It shows positive activity in the following pathways: SR-HSE. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | [H][C@]12SC(C)(C)[C@H](C(=O)O)N1C(=O)[C@@]2([H])NC(=O)Cc1ccccc1.[H][C@]12SC(C)(C)[C@H](C(=O)O)N1C(=O)[C@@]2([H])NC(=O)Cc1ccccc1.c1ccc(CNCCNCc2ccccc2)cc1 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | Cl.c1ccc2c(c1)CCCC2C1=NCCN1 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | C=CC(=O)OCC(O)COc1ccccc1 | This compound is toxic. It shows positive activity in the following pathways: NR-PPAR-gamma. |
Evaluate the clinical safety of this compound regarding FDA approval and clinical toxicity risk. | CCC(C)C1(CC)C(=O)NC(=O)NC1=O | This compound is not FDA approved, but does not have recorded severe clinical toxicity. |
Evaluate the clinical safety of this compound regarding FDA approval and clinical toxicity risk. | Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O | This compound is not FDA approved, but does not have recorded severe clinical toxicity. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | O=Cc1ccccc1S(=O)(=O)[O-].[Na+] | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCC(C)C1N=C(C)C(C)S1 | This compound is toxic. It shows positive activity in the following pathways: CVfold. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | Clc1c(Cl)c(Cl)c(Cl)c(Cl)c1Cl | This compound is toxic. It shows positive activity in the following pathways: CVfold. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC=C(CC)C(=O)NC(N)=O | This compound is toxic. It shows positive activity in the following pathways: NR-ER. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | [H][C@@]1(O)[C@@]([H])(O)[C@]([H])(Oc2ccc3c(C)cc(=O)oc3c2)SC[C@@]1([H])O | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | [As]#[In] | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | COc1ccc(/C(C)=C/C(=O)O)c(OC)c1 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCCCC1CCC(=O)O1 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O | This compound is toxic. It shows positive activity in the following pathways: CVfold. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCN(CC)CCNC(=O)c1ccc(NS(C)(=O)=O)cc1.Cl | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCCCCCCCCCCCSC | This compound is toxic. It shows positive activity in the following pathways: CVfold. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | c1ccc(-c2ccccn2)nc1 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC1CC(OC(=O)C(O)c2ccccc2)CC(C)(C)N1C.Cl | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CN(C)CCC=C1c2ccccc2CCc2ccccc21.Cl | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCCCCCNCCCCCC | This compound is toxic. It shows positive activity in the following pathways: CVfold. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | C=CCN=C=S | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | O=C(c1ccccc1)c1cccc(O)c1 | This compound is toxic. It shows positive activity in the following pathways: NR-ER, NR-ER-LBD, SR-MMP. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | C/C=C/C=C/C(=O)[O-].[K+] | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | Cc1cc(=O)[nH]o1 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | C[N+]1([O-])CCOCC1 | This compound shows no significant toxicity across the tested biological pathways. |
Evaluate the clinical safety of this compound regarding FDA approval and clinical toxicity risk. | CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)([O-])[O-])n1 | This compound is not FDA approved, but does not have recorded severe clinical toxicity. |
Identify the potential clinical side effects associated with this chemical compound. | C1CC(OC1CO)N2C=CC(=NC2=O)N | This compound may cause the following side effects: Hepatobiliary disorders, Metabolism and nutrition disorders, Eye disorders, Investigations, Musculoskeletal and connective tissue disorders, Gastrointestinal disorders, Social circumstances, Immune system disorders, Reproductive system and breast disorders, General di... |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCCCCCO | This compound shows no significant toxicity across the tested biological pathways. |
Identify the potential clinical side effects associated with this chemical compound. | C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N | This compound may cause the following side effects: Hepatobiliary disorders, Metabolism and nutrition disorders, Eye disorders, Investigations, Musculoskeletal and connective tissue disorders, Gastrointestinal disorders, Social circumstances, Immune system disorders, Reproductive system and breast disorders, Neoplasms ... |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | Cc1ccc(C=C2C(=O)C3CCC2C3(C)C)cc1 | This compound shows no significant toxicity across the tested biological pathways. |
Identify the potential clinical side effects associated with this chemical compound. | CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C | This compound may cause the following side effects: Hepatobiliary disorders, Metabolism and nutrition disorders, Investigations, Musculoskeletal and connective tissue disorders, Gastrointestinal disorders, Immune system disorders, Reproductive system and breast disorders, Neoplasms benign, malignant and unspecified (in... |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CN(C)C(=O)CCSC(SCCC(=O)[O-])c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+] | This compound is toxic. It shows positive activity in the following pathways: NR-AhR, NR-ER, SR-ATAD5. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | O=C(OCCOCCOC(=O)c1ccccc1)c1ccccc1 | This compound is toxic. It shows positive activity in the following pathways: CVfold. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC(C)(C#N)/N=N/C(C)(C)C#N | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | C[C@@H](O)[C@H](N)C(=O)O | This compound shows no significant toxicity across the tested biological pathways. |
Evaluate the clinical safety of this compound regarding FDA approval and clinical toxicity risk. | Nc1cc[nH+]cc1 | This compound is not FDA approved, but does not have recorded severe clinical toxicity. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCOC(=O)COc1ccc(C)cc1 | This compound is toxic. It shows positive activity in the following pathways: CVfold, SR-HSE. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC(=C(CCOP(=O)(O)O)SC(=O)c1ccccc1)N(C=O)Cc1cnc(C)nc1N | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](OC(=O)CCC(C)C)CC[C@@]21[H] | This compound is toxic. It shows positive activity in the following pathways: NR-AR, NR-AR-LBD, NR-ER, NR-ER-LBD. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCCCn1cc[n+](C)c1.F[B-](F)(F)F | This compound is toxic. It shows positive activity in the following pathways: SR-ARE. |
Evaluate the clinical safety of this compound regarding FDA approval and clinical toxicity risk. | COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1 | This compound is not FDA approved, but does not have recorded severe clinical toxicity. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | C/C=C/C=C/CO | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O | This compound shows no significant toxicity across the tested biological pathways. |
Evaluate the clinical safety of this compound regarding FDA approval and clinical toxicity risk. | CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)[O-] | This compound is not FDA approved, but does not have recorded severe clinical toxicity. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC1(c2ccc(Oc3ccccc3)cc2)OC(=O)N(Nc2ccccc2)C1=O | This compound is toxic. It shows positive activity in the following pathways: SR-ARE, SR-MMP. |
Evaluate the clinical safety of this compound regarding FDA approval and clinical toxicity risk. | COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CC[NH+]3C[C@H]2C[C@@H](OC(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC | This compound is not FDA approved, but does not have recorded severe clinical toxicity. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O | This compound shows no significant toxicity across the tested biological pathways. |
Identify the potential clinical side effects associated with this chemical compound. | C1C(C(C(C(N1CCO)CO)O)O)O | This compound may cause the following side effects: Gastrointestinal disorders, Skin and subcutaneous tissue disorders. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCC(OCCCOC)OC(C)=O | This compound shows no significant toxicity across the tested biological pathways. |
Identify the potential clinical side effects associated with this chemical compound. | CN1CCN(CC1)C2=C3C=CC=CC3=NC4=C(N2)C=C(C=C4)Cl | This compound may cause the following side effects: Hepatobiliary disorders, Metabolism and nutrition disorders, Eye disorders, Investigations, Musculoskeletal and connective tissue disorders, Gastrointestinal disorders, Immune system disorders, Reproductive system and breast disorders, Neoplasms benign, malignant and ... |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC(O)(c1ccc(Cl)cc1)c1ccc(Cl)cc1 | This compound is toxic. It shows positive activity in the following pathways: SR-MMP. |
Identify the potential clinical side effects associated with this chemical compound. | CCCCCCCCCCCCCCCCCCCCCCO | This compound may cause the following side effects: General disorders and administration site conditions, Skin and subcutaneous tissue disorders, Nervous system disorders. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | [H][C@]12SC(C)(C)[C@H](C(=O)O)N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)N1CCN(S(C)(=O)=O)C1=O)c1ccccc1 | This compound is toxic. It shows positive activity in the following pathways: NR-AR, NR-ER. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | N=C(N)NS(=O)(=O)c1ccc(N)cc1 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | O=C(NCCN1CCOCC1)c1ccc(Cl)cc1 | This compound is toxic. It shows positive activity in the following pathways: CVfold. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | COP(=S)(OC)Oc1nc(Cl)c(Cl)cc1Cl | This compound is toxic. It shows positive activity in the following pathways: SR-MMP. |
Evaluate the clinical safety of this compound regarding FDA approval and clinical toxicity risk. | O=S([O-])CNc1ccc(S(=O)(=O)c2ccc(NCS(=O)[O-])cc2)cc1 | This compound is not FDA approved, but does not have recorded severe clinical toxicity. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC(C)Cc1ccc([C@H](C)C(=O)O)cc1 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | O=S(=O)([O-])[O-].[Fe+2] | This compound shows no significant toxicity across the tested biological pathways. |
Evaluate the clinical safety of this compound regarding FDA approval and clinical toxicity risk. | C=C(c1ccc(C(=O)[O-])cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C | This compound is not FDA approved, but does not have recorded severe clinical toxicity. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | O=P(O)(O)Oc1ccccc1 | This compound shows no significant toxicity across the tested biological pathways. |
Identify the potential clinical side effects associated with this chemical compound. | CC(=O)[O-].CC(=O)[O-].[Ca+2] | This compound may cause the following side effects: Metabolism and nutrition disorders, Gastrointestinal disorders, Immune system disorders, General disorders and administration site conditions, Skin and subcutaneous tissue disorders, Psychiatric disorders, Nervous system disorders. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | O=C(Cl)/C=C/C(=O)Cl | This compound is toxic. It shows positive activity in the following pathways: SR-ARE. |
Evaluate the clinical safety of this compound regarding FDA approval and clinical toxicity risk. | C/C1=C2/N=C(/C=C3\N/C(=C(/C)C4=N[C@@](C)(C5N=C1[C@](C)(CCC(=O)NC[C@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O | This compound is not FDA approved, but does not have recorded severe clinical toxicity. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC(=O)N(CC(C)C(=O)O)c1c(I)cc(I)c(N)c1I | This compound shows no significant toxicity across the tested biological pathways. |
Identify the potential clinical side effects associated with this chemical compound. | C1CC(CCC1CN)C(=O)O | This compound may cause the following side effects: Eye disorders, Investigations, Musculoskeletal and connective tissue disorders, Gastrointestinal disorders, Immune system disorders, General disorders and administration site conditions, Vascular disorders, Blood and lymphatic system disorders, Skin and subcutaneous t... |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | Cc1c(C(=O)NCCO)[n+]([O-])c2ccccc2[n+]1[O-] | This compound is toxic. It shows positive activity in the following pathways: CVfold. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | [H][C@]1([C@H](O)COC(=O)CCCCCCC/C=C\CCCCCCCC)OC[C@H](O)[C@H]1O | This compound shows no significant toxicity across the tested biological pathways. |
Identify the potential clinical side effects associated with this chemical compound. | CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34.C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O | This compound may cause the following side effects: Metabolism and nutrition disorders, Eye disorders, Investigations, Gastrointestinal disorders, Immune system disorders, Reproductive system and breast disorders, Skin and subcutaneous tissue disorders, Congenital, familial and genetic disorders, Psychiatric disorders,... |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | O=c1[nH]c2cc(Cl)ccc2o1 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCCCC(CC)COCCO | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | ClC(Cl)=C(Cl)C(Cl)=C(Cl)Cl | This compound shows no significant toxicity across the tested biological pathways. |
Evaluate the clinical safety of this compound regarding FDA approval and clinical toxicity risk. | Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12 | This compound is not FDA approved, but does not have recorded severe clinical toxicity. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCCCS | This compound is toxic. It shows positive activity in the following pathways: CVfold. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CC(C)=CC=O | This compound shows no significant toxicity across the tested biological pathways. |
Evaluate the clinical safety of this compound regarding FDA approval and clinical toxicity risk. | CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1 | This compound is not FDA approved, but does not have recorded severe clinical toxicity. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CNC.Cl | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | [Na+].[O-]c1ccccc1 | This compound is toxic. It shows positive activity in the following pathways: CVfold. |
Identify the potential clinical side effects associated with this chemical compound. | C=CC(CCC(=O)O)N | This compound may cause the following side effects: Hepatobiliary disorders, Metabolism and nutrition disorders, Eye disorders, Investigations, Musculoskeletal and connective tissue disorders, Gastrointestinal disorders, Social circumstances, Immune system disorders, Reproductive system and breast disorders, General di... |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCN(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1 | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | COCCO | This compound shows no significant toxicity across the tested biological pathways. |
Identify the potential clinical side effects associated with this chemical compound. | CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4 | This compound may cause the following side effects: Metabolism and nutrition disorders, Eye disorders, Investigations, Musculoskeletal and connective tissue disorders, Gastrointestinal disorders, Immune system disorders, Neoplasms benign, malignant and unspecified (incl cysts and polyps), General disorders and administ... |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCN1C(=CC=Cc2sc3ccccc3[n+]2CC)Sc2ccccc21.[I-] | This compound is toxic. It shows positive activity in the following pathways: SR-p53. |
Evaluate the clinical safety of this compound regarding FDA approval and clinical toxicity risk. | CCc1c2c(nc3ccc(OC(=O)N4CCC([NH+]5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC | This compound is not FDA approved, but does not have recorded severe clinical toxicity. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCC(=O)C(=O)CC | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | [H][C@@]12C(=O)CC[C@]13CC[C@@]([H])(C)[C@@]2(C)[C@H](OC(=O)CSC(C)(C)CNC(=O)[C@H](N)C(C)C)C[C@@](C)(C=C)[C@@H](O)[C@@H]3C | This compound shows no significant toxicity across the tested biological pathways. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCCCCCCCCC(C)C=O | This compound is toxic. It shows positive activity in the following pathways: NR-PPAR-gamma. |
Analyze the chemical structure and determine its toxicity profile across biological pathways. | CCCCCCCC/C=C\CCCCCCCC(=O)OCCCC | This compound is toxic. It shows positive activity in the following pathways: CVfold. |
Identify the potential clinical side effects associated with this chemical compound. | CC(C)NC(=O)C1=CC=C(C=C1)CNNC | This compound may cause the following side effects: Hepatobiliary disorders, Metabolism and nutrition disorders, Eye disorders, Investigations, Musculoskeletal and connective tissue disorders, Gastrointestinal disorders, Social circumstances, Immune system disorders, Reproductive system and breast disorders, Neoplasms ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.